| Nome |
# |
|
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease, file e309ade3-dd88-3969-e053-3a05fe0a2c94
|
285
|
|
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice, file e309ade1-ed74-3969-e053-3a05fe0a2c94
|
282
|
|
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release, file e309ade0-9bcd-3969-e053-3a05fe0a2c94
|
124
|
|
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease, file e309ade3-db82-3969-e053-3a05fe0a2c94
|
108
|
|
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists, file e309ade3-f974-3969-e053-3a05fe0a2c94
|
99
|
|
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease, file 097ccc8a-9bab-450f-9e98-c5824f903d52
|
85
|
|
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists, file e309ade1-b603-3969-e053-3a05fe0a2c94
|
78
|
|
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice, file e309ade1-5825-3969-e053-3a05fe0a2c94
|
73
|
|
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors, file e309ade0-9cc5-3969-e053-3a05fe0a2c94
|
67
|
|
Role of LRRK2 in the regulation of dopamine receptor trafficking, file e309ade1-a6c4-3969-e053-3a05fe0a2c94
|
61
|
|
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia, file e309ade1-acb4-3969-e053-3a05fe0a2c94
|
59
|
|
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling, file e309ade2-701e-3969-e053-3a05fe0a2c94
|
59
|
|
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models, file e309ade2-a3ae-3969-e053-3a05fe0a2c94
|
52
|
|
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter, file e309ade5-0769-3969-e053-3a05fe0a2c94
|
49
|
|
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease, file e309ade1-0e3d-3969-e053-3a05fe0a2c94
|
48
|
|
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain, file e309ade0-a22b-3969-e053-3a05fe0a2c94
|
45
|
|
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease, file e309ade1-a23e-3969-e053-3a05fe0a2c94
|
44
|
|
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes, file e309ade2-5f1e-3969-e053-3a05fe0a2c94
|
42
|
|
Autophagy and LRRK2 in the Aging Brain, file e309ade2-7416-3969-e053-3a05fe0a2c94
|
41
|
|
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia, file e309ade5-0042-3969-e053-3a05fe0a2c94
|
36
|
|
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4, file e309ade1-f664-3969-e053-3a05fe0a2c94
|
34
|
|
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity, file e309ade3-fe3e-3969-e053-3a05fe0a2c94
|
34
|
|
Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice, file e309ade5-7160-3969-e053-3a05fe0a2c94
|
17
|
|
Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation, file e309ade2-a37c-3969-e053-3a05fe0a2c94
|
14
|
|
Managing Parkinson's disease: moving ON with NOP, file e309ade2-7490-3969-e053-3a05fe0a2c94
|
12
|
|
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates, file e309ade2-a346-3969-e053-3a05fe0a2c94
|
12
|
|
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance, file e309ade4-d80f-3969-e053-3a05fe0a2c94
|
12
|
|
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia, file e309ade0-a123-3969-e053-3a05fe0a2c94
|
11
|
|
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia, file ed9f748f-2295-43dd-958c-1fca8b754276
|
11
|
|
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity, file e309ade1-5207-3969-e053-3a05fe0a2c94
|
10
|
|
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats, file e309ade3-287f-3969-e053-3a05fe0a2c94
|
10
|
|
Early dysfunction of substantia nigra dopamine neurons in the parkinq311x mouse, file e309ade4-f037-3969-e053-3a05fe0a2c94
|
10
|
|
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging, file e309ade0-460c-3969-e053-3a05fe0a2c94
|
9
|
|
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata, file e309ade4-f031-3969-e053-3a05fe0a2c94
|
9
|
|
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity, file e309ade5-310c-3969-e053-3a05fe0a2c94
|
8
|
|
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives, file e309ade2-5f84-3969-e053-3a05fe0a2c94
|
7
|
|
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia, file e309ade5-0987-3969-e053-3a05fe0a2c94
|
7
|
|
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands, file e309ade0-4197-3969-e053-3a05fe0a2c94
|
5
|
|
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex, file e309ade0-ca5e-3969-e053-3a05fe0a2c94
|
5
|
|
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo, file e309ade5-076b-3969-e053-3a05fe0a2c94
|
5
|
|
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity, file e309ade3-2885-3969-e053-3a05fe0a2c94
|
4
|
|
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology, file 660767c4-c52f-4353-8780-a91df8f457d4
|
3
|
|
null, file e309ade0-2862-3969-e053-3a05fe0a2c94
|
3
|
|
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity, file e309ade0-341d-3969-e053-3a05fe0a2c94
|
3
|
|
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease, file e309ade0-9fb4-3969-e053-3a05fe0a2c94
|
3
|
|
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity, file e309ade0-a262-3969-e053-3a05fe0a2c94
|
3
|
|
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors, file e309ade4-0894-3969-e053-3a05fe0a2c94
|
3
|
|
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation, file e309ade5-3c64-3969-e053-3a05fe0a2c94
|
3
|
|
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway, file e309ade0-224b-3969-e053-3a05fe0a2c94
|
2
|
|
null, file e309ade0-2863-3969-e053-3a05fe0a2c94
|
2
|
|
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats, file e309ade0-32cf-3969-e053-3a05fe0a2c94
|
2
|
|
null, file e309ade0-3f39-3969-e053-3a05fe0a2c94
|
2
|
|
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111, file e309ade0-4198-3969-e053-3a05fe0a2c94
|
2
|
|
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity, file e309ade2-7421-3969-e053-3a05fe0a2c94
|
2
|
|
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease, file e309ade2-a773-3969-e053-3a05fe0a2c94
|
2
|
|
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease, file e309ade3-db81-3969-e053-3a05fe0a2c94
|
2
|
|
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease, file e309ade3-f75e-3969-e053-3a05fe0a2c94
|
2
|
|
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice, file e309ade3-fd2a-3969-e053-3a05fe0a2c94
|
2
|
|
Modeling Parkinson's disease in LRRK2 mice: Focus on synaptic dysfunction and the autophagylysosomal pathway, file e309ade5-a0c9-3969-e053-3a05fe0a2c94
|
2
|
|
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter, file a971c687-0aa0-4ec1-9f60-aaeaffd12cbf
|
1
|
|
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior, file e309ade0-22e5-3969-e053-3a05fe0a2c94
|
1
|
|
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor, file e309ade0-246b-3969-e053-3a05fe0a2c94
|
1
|
|
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease, file e309ade0-2f55-3969-e053-3a05fe0a2c94
|
1
|
|
Loss of cortical GABA terminals in Unverricht–Lundborg disease, file e309ade0-3641-3969-e053-3a05fe0a2c94
|
1
|
|
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor, file e309ade0-38c8-3969-e053-3a05fe0a2c94
|
1
|
|
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease, file e309ade0-3b05-3969-e053-3a05fe0a2c94
|
1
|
|
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum, file e309ade0-460a-3969-e053-3a05fe0a2c94
|
1
|
|
Stimulation of Delta Opioid Receptor and Blockade of
Nociceptin/Orphanin FQ Receptor Synergistically Attenuate
Parkinsonism, file e309ade0-460b-3969-e053-3a05fe0a2c94
|
1
|
|
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats, file e309ade0-4ac5-3969-e053-3a05fe0a2c94
|
1
|
|
Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias, file e309ade0-4d86-3969-e053-3a05fe0a2c94
|
1
|
|
null, file e309ade0-b853-3969-e053-3a05fe0a2c94
|
1
|
|
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia, file e309ade1-07cf-3969-e053-3a05fe0a2c94
|
1
|
|
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism, file e309ade1-1dfb-3969-e053-3a05fe0a2c94
|
1
|
|
Parkinson's disease: no NOP, new hope, file e309ade1-37c3-3969-e053-3a05fe0a2c94
|
1
|
|
NOP receptor ligands and Parkinson’s disease, file e309ade2-5f19-3969-e053-3a05fe0a2c94
|
1
|
|
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease, file e309ade3-707a-3969-e053-3a05fe0a2c94
|
1
|
|
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease, file e309ade3-70d7-3969-e053-3a05fe0a2c94
|
1
|
|
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology, file e309ade5-715e-3969-e053-3a05fe0a2c94
|
1
|
| Totale |
2.045 |